Prelude Therapeutics Inc
$ 4.90
4.70%
07 Aug - close price
- Market Cap 390,262,000 USD
- Current Price $ 4.90
- High / Low $ 4.92 / 4.63
- Stock P/E N/A
- Book Value 0.73
- EPS -1.05
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.40 %
- ROE -0.95 %
- 52 Week High 5.69
- 52 Week Low 0.75
About
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.
Analyst Target Price
$8.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-10 | 2025-11-12 | 2025-08-14 | 2025-05-06 | 2025-03-10 | 2024-11-06 | 2024-08-12 | 2024-05-07 | 2024-02-15 | 2023-11-01 | 2023-08-03 |
| Reported EPS | -0.13 | -0.2 | -0.26 | -0.41 | -0.42 | -0.37 | -0.43 | -0.46 | -0.42 | -0.45 | -0.45 | -0.54 |
| Estimated EPS | -0.27 | -0.13 | -0.35 | -0.43 | -0.46 | -0.4673 | -0.46 | -0.43 | -0.48 | -0.49 | -0.58 | -0.63 |
| Surprise | 0.14 | -0.07 | 0.09 | 0.02 | 0.04 | 0.0973 | 0.03 | -0.03 | 0.06 | 0.04 | 0.13 | 0.09 |
| Surprise Percentage | 51.8519% | -53.8462% | 25.7143% | 4.6512% | 8.6957% | 20.8217% | 6.5217% | -6.9767% | 12.5% | 8.1633% | 22.4138% | 14.2857% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRLD
2026-07-31 07:10:45
This article highlights bullish sentiments from Wall Street analysts on three healthcare companies: Prelude Therapeutics (PRLD), Candel Therapeutics (CADL), and NeuroPace (NPCE). H.C. Wainwright analysts reiterated Buy ratings for all three, setting price targets of $8.00, $23.00, and $20.00 respectively. The article provides details on the analysts' ratings, their average returns, and the consensus price targets for each stock.
2026-07-30 19:42:40
This article provides a comprehensive stock analysis of Prelude Therapeutics Inc (PRLD) by TradingKey, highlighting its healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes high institutional ownership and multiple "Buy" ratings from analysts, with a highest price target of $8.00. The company, a clinical-stage oncology firm, is in a growing phase and specializes in novel precision cancer medicines with a diverse pipeline.
2026-07-30 16:09:32
This article analyzes the financial health of Prelude Therapeutics Inc (PRLD), assigning it a score of 6.29 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is deemed stable, but its operating efficiency is low. Key financial dimensions like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns are assessed, though much of the relevant data has not been disclosed by the company.
2026-07-29 11:42:54
HC Wainwright & Co. has reiterated a "Buy" rating for Prelude Therapeutics (PRLD) with an $8.00 price target, maintaining confidence despite the company's low GF Score™ of 22/100 and a high price-to-sales ratio suggesting overvaluation. The biotech firm specializes in precision oncology with a market cap of $369.55 million, but faces challenges noted in its profitability and growth metrics. Insider activity has been stable, with mixed sentiment among institutional investors.
2026-07-29 08:42:54
This article provides a risk assessment for Prelude Therapeutics Inc (PRLD), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 1.12, ranking 326 out of 385 in the Biotechnology & Medical Research industry, and a beta value of 1.02. The assessment includes various metrics like maximum drawdown, Sharpe ratio, and realized volatility over different periods.
2026-07-28 16:09:32
This article lists several health care stocks that experienced significant movement in Tuesday's pre-market session. It details both gainers, such as Gossamer Bio and Prelude Therapeutics, and losers, including Replimune Group and Nexalin Technology, along with their respective percentage changes and market capitalizations. The article also mentions IQVIA Holdings' rise due to its Q2 earnings report.
